1. AB0079 Independent Validation of 14-3-3ETA Assay Reproducibility, Consistent with Omeract Soluble Biomarker Criteria. (9th June 2015) Authors: Hughes, N.; Boss, S.; Longe, R.; Sohal, P.; Jimenez, C.; Maksymowych, W.P.; Marotta, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0090 Reactivity To Citrullinated Peptide of 14-3-3eta Protein Is Associated with Worse Radiographic Outcomes in Patients with Recent-Onset Inflammatory Arthritis. (15th July 2016) Authors: Carrier, N.; Marotta, A.; Maksymowych, W.P.; Boire, G. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0111 Extracellular 14-3-3 ETA represents a novel rheumatology biomarker and drug target for personalized medicine. (23rd January 2014) Authors: Marotta, A.; Kilani, R.; Ghahary, A.; Maksymowych, W.P. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 644 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0113 The Citrullinome: Enabling Clinical Insights Through the Development of a Pan Reactive Cit-Specific AB. (9th June 2015) Authors: Gui, Y.; Murphy, M.; Maksymowych, W.P.; Marotta, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0152 14-3-3Eta Biomarker Dynamics in CIA Mark Disease Severity in A Non-Interventional Study. (10th June 2014) Authors: Abulrob, A.; Maksymowych, W.P.; Marotta, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 853 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0275 14-3-3 eta is an independent marker of joint damage that complements CRP and anti-CCP. (23rd January 2014) Authors: van der Heijde, D.; Landewé, R.; Allaart, C.F.; Tak, P.P.; Marotta, A.; Maksymowych, W.P. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 653 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0287 Decrease in 14–3–3eta protein levels is correlated with improvement of clinical disease activity in tofacitinib treated early rheumatoid arthritis patients. (12th June 2018) Authors: Shovman, O.; Gilburd, B.; Watad, A.; Amital, H.; Langevitz, P.; Bragazzi, N.L.; Adawi, M.; Pérez, D.; Blank, M.; Biln, N.K.; Marotta, A.; Shoenfeld, Y. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. AB0941 14-3-3ETA Clinical Assays Are Equivalent and RF Does not Interfere with Its Quantitation. (10th June 2014) Authors: Naides, S.J.; Zhukov, O.S.; Popov, J.M.; Abolhosn, R.W.; Lam, K.; Gui, Y.; Maksymowych, W.; Marotta, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 1111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. AB0944 Baseline serum 14-3-3 ETA levels predict ACR50 response to adalimumab therapy in psoriatic arthritis. (23rd January 2014) Authors: Marotta, A.; Kuijk, A.W.; Maksymowych, W.P.; Tak, P.P. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 692 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. AB1029 Serum 14-3-3ETA is Present in JIA and is not Associated with RF+ Polyarthritis. (9th June 2015) Authors: Rosenberg, A.; Maksymowych, W.P.; Gui, Y.; Marotta, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗